XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > $2 by end of December

<< Previous

Bullboard Posts

Next >>

Comment by Anklebiter42on Nov 14, 2021 8:17pm

101 Views

Post# 34125482

RE:RE:RE:$2 by end of December

Spacelab. My prediction......One more week of the Investor roadshow. By the end of the week, David will have transfered the rest of your shares to his institional buddies. The following week the stock price will go up dramatically. We will all make a ton of money (Not you of course).......... and you will continue to try and restructure the company. HAHA......... Garble,,,,,, Garble ...... Garble

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1